Cetaphil Oil Absorbing Spf 30

Octocrylene, Octisalate, Avobenzone


Galderma Laboratories, L.p.
Human Otc Drug
NDC 0299-4123
Cetaphil Oil Absorbing Spf 30 also known as Octocrylene, Octisalate, Avobenzone is a human otc drug labeled by 'Galderma Laboratories, L.p.'. National Drug Code (NDC) number for Cetaphil Oil Absorbing Spf 30 is 0299-4123. This drug is available in dosage form of Lotion. The names of the active, medicinal ingredients in Cetaphil Oil Absorbing Spf 30 drug includes Avobenzone - 3 g/100mL Octisalate - 5 g/100mL Octocrylene - 7 g/100mL . The currest status of Cetaphil Oil Absorbing Spf 30 drug is Active.

Drug Information:

Drug NDC: 0299-4123
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Cetaphil Oil Absorbing Spf 30
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Octocrylene, Octisalate, Avobenzone
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Galderma Laboratories, L.p.
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Lotion
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:AVOBENZONE - 3 g/100mL
OCTISALATE - 5 g/100mL
OCTOCRYLENE - 7 g/100mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: OTC MONOGRAPH FINAL
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 01 Dec, 2011
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 05 May, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: part352
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Galderma Laboratories, L.P.
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:G63QQF2NOX
4X49Y0596W
5A68WGF6WM
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
0299-4123-001 BOTTLE, PUMP in 1 CARTON (0299-4123-00) / 118 mL in 1 BOTTLE, PUMP01 Dec, 2011N/ANo
0299-4123-0510 mL in 1 TUBE (0299-4123-05)01 Dec, 2011N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Product Elements:

Cetaphil oil absorbing spf 30 octocrylene, octisalate, avobenzone octocrylene octocrylene octisalate octisalate avobenzone avobenzone water glycerin dimethicone diisopropyl sebacate silicon dioxide aluminum starch octenylsuccinate pentylene glycol sodium stearoyl glutamate phenoxyethanol caprylyl glycol enoxolone panthenol trolamine allantoin potassium sorbate zinc gluconate xanthan gum edetate disodium dimethiconol (2000 cst) hydroxypalmitoyl sphinganine isopropyl lauroyl sarcosinate poly(methyl methacrylate; 450000 mw) polysorbate 61 sucrose tristearate carbomer homopolymer type a (allyl pentaerythritol crosslinked) .alpha.-tocopherol p55322-1 carton artwork

Indications and Usage:

Use(s) helps prevent sunburn. if used as directed with other sun protection measures (see directions ), decreases the risk of skin cancer and early skin aging caused by the sun.

Warnings:

Warnings for external use only. do not use on damaged or broken skin. stop use and ask a doctor if rash occurs. when using this product, keep out of eyes. rinse with water to remove. keep out of reach of children. if swallowed, get medical help or contact a poison control center right away.

Dosage and Administration:

Directions • apply liberally 15 minutes before sun exposure. • use a water resistant sunscreen if swimming or sweating. • reapply at least every 2 hours. • children under 6 months: ask a doctor. sun protection measures: spending time in the sun increases your risk of cancer and early skin aging. to decrease this risk, regularly use a sunscreen with a broad spectrum spf value of 15 or higher and other sun protection measures including: • limit time in the sun, especially 10am - 2pm. • wear long-sleeved shirts, pants, hats, and sunglasses.

Package Label Principal Display Panel:

Principle display panel - 4oz carton #1 doctor recommended sensitive skincare brand cetaphil ® derma control tm oil absorbing moisturizer with sunscreen broad spectrum spf 30 oily, sensitive skin clinically proven to reduce shine and hydrate without irritation with added uva/uvb protection mattifying and soothing zinc technology skin cancer foundation logo 4 fl oz (118 ml)

Further Questions:

Questions? 1-866-735-4137 distributed by: galderma laboratories, l.p. fort worth, tx 76177 all trademarks are the property of their respective owners made in canada cetaphil.com


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.